Phaseline

Companies › Charm Therapeutics

Charm Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CHM-029
Protein degradation targeting NPM1, KMT2A, or NUP98 rearranged AML
–Phase 1AML (Acute Myeloid Leukemia)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07751991CHM-029Phase 1AML (Acute Myeloid Leukemia)OncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.